Answers are grounded in this paper and cite their sources.
Objective To examine when cell‐free DNA (cfDNA) was drawn relative to the first‐trimester scan, whether the phenotype redirected genetic testing, whether a positive result’s meaning varied with condition and phenotype, and what order changes when the same components are used. Methods Observed : 11,270 singleton pregnancies scanned at 11–13 +6 weeks (2009–2026); chart review of those with nuchal translucency (NT) 3.5 mm or more and cfDNA ( n = 19); positive predictive value (PPV) across 1739 pregnancies with a cfDNA result. Modelled: five hypothetical pathways applied to 11,111 pregnancies. Abnormalities were known only where tested, so modelled counts are eligibility for referral and not detection rates. Results Observed : cfDNA became available in November 2015 and was used in 7.6% of the 2016–2026 cohort; 40.2% of samples preceded the scan. Of those 19 pregnancies, 16 were sampled before any phenotyping and none later; all five low‐risk results were superseded. PPV fell from 95% (trisomy 21) to 17% (sex chromosome aneuploidies). Modelled: both pathways had identical eligibility by design, differing by 261 additional modelled cfDNA tests that could not alter referral. Conclusion Order changed neither modelled eligibility nor assay capability, but determined whether screening information preceded the phenotype that establishes whether it is needed.
No takes yet. Share an insight, caveat, or question.
Mureșan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: